OM:XVIVOMedical Equipment
Xvivo Perfusion (OM:XVIVO) Margin Reset To 3.1% TTM Tests Premium Growth Narrative
Xvivo Perfusion (OM:XVIVO) has wrapped up FY 2025 with fourth quarter revenue of SEK 226.1 million and basic EPS of SEK 1.00, while trailing twelve month revenue came in at SEK 812.2 million with EPS of SEK 0.80. Over recent periods the company has seen quarterly revenue move from SEK 198.5 million in Q3 2024 to SEK 227.6 million in Q4 2024 and then SEK 218.6 million, SEK 178.3 million, SEK 189.1 million and SEK 226.1 million through Q4 2025, with EPS shifting alongside those swings...